COMPANY PROFILE

Adenocyte

LINFU® enhances epithelial cell exfoliation with low-intensity ultrasound, improving cytological specimens for cancer screening

IsraelFounded 2020Health

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Adenocyte

Adenocyte is focused on improving the early detection of dysplasia and cancer through enhanced cytological specimens. The company's core technology utilizes a specially designed, low-intensity, non-focused ultrasound beam.

This FDA-cleared device is applied extracorporeally in a brief procedure to increase the natural rate of epithelial cell exfoliation into a surrounding body fluid. The result is a dramatically improved sample for laboratory analysis.

The primary application is to aid in the early detection and prevention of cancers, with a specific mention of pancreatic cancer. By providing a better sample, the company aims to increase the effectiveness of cancer screening procedures.

The company's Director of Technical Operations, Aaron Rutenberg, brings over a decade of experience in coordinating R&D projects for biomedical firms, with a background in diagnostics and laboratory management.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Israel
Employees: 3
Open positions: None listed
Dealroom signal: 24.0/100
Industry: Health
Sector: Health, Oncology, Ultrasound Sensors, medical testing
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	May 2026	$10M	$40M	IGan Partners	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Adenocyte website traffic

Latest recorded traffic for Adenocyte is 910 monthly website visits, up 139.5% over the last three months.

Latest monthly visits910 3-month web change+139.5%

Monthly website visitsOct 2025–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GGGC GenomeGenomic diagnostics for personalized healthcare and oncology	Yongin-si, South Korea	Operational	33	—	—
ONOncoSwabDevelops a non-invasive, easy-to-use test for early lung cancer detection	San Francisco, United States	Operational
ACAccuTheranosticsAccuTheranostics, Inc. offers a full line of laboratory tests designed to provide information to tailor treatment to the individual patient’s cancer	Buffalo, United States	Operational
LALabgenomicsMolecular and genetic diagnostic testing services provider.	South Korea	Operational
MTMetabolomic TechnologiesCommitted to developing non-invasive in-vitro diagnostics to meet patients' greatest unmet needs	Edmonton, Canada	Operational
LTLuminor Medical TechnologiesCannabis-based formulations for health and wellness products	Winnipeg, Canada	Operational
NHNoviogendix HoldingProvider of molecular diagnostics and services to physicians, clinics, and hospitals to personalize the diagnosis and treatment of cancer	Irvine, United States	Acquired
MUMultiplexDXEliminating cancer misdiagnosis by launching a new diagnostic test in 2023 and operating a boutique oligo house	Rockville, United States	Operational